Drug Profile
D 0120
Alternative Names: D 0120-NA; D-0120Latest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator InventisBio
- Class Antigouts; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout
- Phase I/II Hyperuricaemia
Most Recent Events
- 17 Apr 2023 Phase-II clinical trials in Gout (Combination therapy, In adults, In the elderly) in USA (PO) (NCT05665699)
- 19 Dec 2022 InventisBio plans a phase II trial (Combination therapy, In adults, In the elderly) for Gout (PO) in February 2023 (NCT05665699)
- 23 Apr 2022 InventisBio completes a phase I trial in Healthy volunteers in USA (PO) (NCT05360628)